JP2003500399A - 免疫抑制活性を有する置換フェニル化合物および医薬組成物 - Google Patents
免疫抑制活性を有する置換フェニル化合物および医薬組成物Info
- Publication number
- JP2003500399A JP2003500399A JP2000619786A JP2000619786A JP2003500399A JP 2003500399 A JP2003500399 A JP 2003500399A JP 2000619786 A JP2000619786 A JP 2000619786A JP 2000619786 A JP2000619786 A JP 2000619786A JP 2003500399 A JP2003500399 A JP 2003500399A
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- methyl
- phenyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 12
- 230000001506 immunosuppresive effect Effects 0.000 title claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 165
- 238000000034 method Methods 0.000 claims abstract description 35
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 6
- -1 cyano, nitro, amino, hydroxyl Chemical group 0.000 claims description 76
- 239000000126 substance Substances 0.000 claims description 61
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 47
- 229910052739 hydrogen Inorganic materials 0.000 claims description 34
- 238000006243 chemical reaction Methods 0.000 claims description 32
- 150000003839 salts Chemical class 0.000 claims description 32
- 239000001257 hydrogen Substances 0.000 claims description 31
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 28
- 239000012453 solvate Substances 0.000 claims description 24
- 125000000623 heterocyclic group Chemical group 0.000 claims description 23
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 17
- 229910052731 fluorine Inorganic materials 0.000 claims description 17
- 125000001424 substituent group Chemical group 0.000 claims description 17
- 125000001153 fluoro group Chemical group F* 0.000 claims description 16
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- 150000002431 hydrogen Chemical class 0.000 claims description 14
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 12
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 12
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 claims description 12
- 125000005843 halogen group Chemical group 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 125000004434 sulfur atom Chemical group 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 6
- 239000000654 additive Substances 0.000 claims description 6
- 230000000996 additive effect Effects 0.000 claims description 6
- 235000019270 ammonium chloride Nutrition 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 claims description 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 5
- 230000000414 obstructive effect Effects 0.000 claims description 5
- 208000023504 respiratory system disease Diseases 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- WSBRAHWNJBXXJM-UHFFFAOYSA-N 2-(3,4-difluoroanilino)-n-[2-methyl-5-(piperazin-1-ylmethyl)phenyl]acetamide;trihydrochloride Chemical compound Cl.Cl.Cl.C1=C(NC(=O)CNC=2C=C(F)C(F)=CC=2)C(C)=CC=C1CN1CCNCC1 WSBRAHWNJBXXJM-UHFFFAOYSA-N 0.000 claims description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
- FZAPMZDUDSJAMS-UHFFFAOYSA-N Cl.Cl.Cl.CC1=CC=C(N2CCNCC2)C=C1NC(=O)CNC1=CC=C(F)C(F)=C1 Chemical compound Cl.Cl.Cl.CC1=CC=C(N2CCNCC2)C=C1NC(=O)CNC1=CC=C(F)C(F)=C1 FZAPMZDUDSJAMS-UHFFFAOYSA-N 0.000 claims description 4
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- UQUFDVZPPJJQPT-UHFFFAOYSA-N n-[3-[(4-acetylpiperazin-1-yl)methyl]-2-methylphenyl]-2-(3,4-difluoroanilino)acetamide Chemical compound C1CN(C(=O)C)CCN1CC1=CC=CC(NC(=O)CNC=2C=C(F)C(F)=CC=2)=C1C UQUFDVZPPJJQPT-UHFFFAOYSA-N 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- ZZRXVPISIXHDIM-YDULTXHLSA-N 2-(3,4-difluoroanilino)-N-[2-methyl-4-[[(2S)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]methyl]phenyl]acetamide trihydrochloride Chemical compound Cl.Cl.Cl.Cc1cc(CN2CCC[C@H]2CN2CCCC2)ccc1NC(=O)CNc1ccc(F)c(F)c1 ZZRXVPISIXHDIM-YDULTXHLSA-N 0.000 claims description 3
- QTYKWYPHJGMZRN-UHFFFAOYSA-N 2-(3,4-difluoroanilino)-n-[2-methyl-5-[(4-pyrimidin-2-ylpiperazin-1-yl)methyl]phenyl]acetamide Chemical compound C1=C(NC(=O)CNC=2C=C(F)C(F)=CC=2)C(C)=CC=C1CN(CC1)CCN1C1=NC=CC=N1 QTYKWYPHJGMZRN-UHFFFAOYSA-N 0.000 claims description 3
- YYCKKWSLUGKVSO-KRWDZBQOSA-N 2-(3,4-difluoroanilino)-n-[5-[[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]methyl]-2-methylphenyl]acetamide Chemical compound C1=C(NC(=O)CNC=2C=C(F)C(F)=CC=2)C(C)=CC=C1CN1CCC[C@H]1CO YYCKKWSLUGKVSO-KRWDZBQOSA-N 0.000 claims description 3
- COORCOHYLVIKTJ-UHFFFAOYSA-N 3-[[2-(3,4-difluoroanilino)acetyl]amino]-n-[2-(dimethylamino)ethyl]-2-methylbenzamide Chemical compound CN(C)CCNC(=O)C1=CC=CC(NC(=O)CNC=2C=C(F)C(F)=CC=2)=C1C COORCOHYLVIKTJ-UHFFFAOYSA-N 0.000 claims description 3
- RXLPAMAJKXAMIZ-UHFFFAOYSA-N Cl.Cl.Cl.C1=C(F)C(F)=CC=C1NCC(=O)NC1=CC(N2CCNCC2)=CC=C1Cl Chemical compound Cl.Cl.Cl.C1=C(F)C(F)=CC=C1NCC(=O)NC1=CC(N2CCNCC2)=CC=C1Cl RXLPAMAJKXAMIZ-UHFFFAOYSA-N 0.000 claims description 3
- KNLCYAAXQKYIKS-UHFFFAOYSA-N Cl.Cl.Cl.CC1=CC=C(N2CC(N)CC2)C=C1NC(=O)CNC1=CC=C(F)C(F)=C1 Chemical compound Cl.Cl.Cl.CC1=CC=C(N2CC(N)CC2)C=C1NC(=O)CNC1=CC=C(F)C(F)=C1 KNLCYAAXQKYIKS-UHFFFAOYSA-N 0.000 claims description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 239000003054 catalyst Substances 0.000 claims description 3
- 125000004122 cyclic group Chemical group 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 229910052763 palladium Inorganic materials 0.000 claims description 3
- OQJBFFCUFALWQL-BUHFOSPRSA-N (ne)-n-(piperidine-1-carbonylimino)piperidine-1-carboxamide Chemical compound C1CCCCN1C(=O)\N=N\C(=O)N1CCCCC1 OQJBFFCUFALWQL-BUHFOSPRSA-N 0.000 claims description 2
- 206010062016 Immunosuppression Diseases 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 229940100198 alkylating agent Drugs 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 2
- 229910000073 phosphorus hydride Inorganic materials 0.000 claims description 2
- 125000003944 tolyl group Chemical group 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 105
- 239000000243 solution Substances 0.000 description 78
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 48
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 43
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- 238000004949 mass spectrometry Methods 0.000 description 35
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 33
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 26
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 25
- 239000000203 mixture Substances 0.000 description 25
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 22
- 239000012044 organic layer Substances 0.000 description 21
- 239000000047 product Substances 0.000 description 21
- 239000007787 solid Substances 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 239000011734 sodium Substances 0.000 description 14
- 238000000354 decomposition reaction Methods 0.000 description 13
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 12
- 238000002844 melting Methods 0.000 description 12
- 230000008018 melting Effects 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- 238000001816 cooling Methods 0.000 description 10
- 238000010898 silica gel chromatography Methods 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 239000012458 free base Substances 0.000 description 8
- 239000012299 nitrogen atmosphere Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 239000000460 chlorine Substances 0.000 description 7
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical group [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 7
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 229910052801 chlorine Inorganic materials 0.000 description 6
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 6
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 5
- OQJBFFCUFALWQL-UHFFFAOYSA-N n-(piperidine-1-carbonylimino)piperidine-1-carboxamide Chemical compound C1CCCCN1C(=O)N=NC(=O)N1CCCCC1 OQJBFFCUFALWQL-UHFFFAOYSA-N 0.000 description 5
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 5
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 4
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- BURJIEWNHIKROD-FWDYTFEUSA-N [[(2r,3r,4r,5s)-5-(6-aminopurin-9-yl)-4,5-dibenzoyl-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C([C@@]1(O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@]1(N1C=2N=CN=C(C=2N=C1)N)C(=O)C=1C=CC=CC=1)C1=CC=CC=C1 BURJIEWNHIKROD-FWDYTFEUSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 229940043279 diisopropylamine Drugs 0.000 description 4
- 239000011737 fluorine Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 4
- ZVULIZVXYJVIMD-UHFFFAOYSA-N 2-(3-chloro-4-fluoroanilino)-n-(5-hydroxy-2-methylphenyl)acetamide Chemical compound CC1=CC=C(O)C=C1NC(=O)CNC1=CC=C(F)C(Cl)=C1 ZVULIZVXYJVIMD-UHFFFAOYSA-N 0.000 description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
- 239000005695 Ammonium acetate Substances 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical group OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 229940043376 ammonium acetate Drugs 0.000 description 3
- 235000019257 ammonium acetate Nutrition 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 3
- 229960005542 ethidium bromide Drugs 0.000 description 3
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 3
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- PWQLFIKTGRINFF-UHFFFAOYSA-N tert-butyl 4-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(O)CC1 PWQLFIKTGRINFF-UHFFFAOYSA-N 0.000 description 3
- FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 3
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 3
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- YLBWRMSQRFEIEB-VIFPVBQESA-N 1-[[(2s)-pyrrolidin-2-yl]methyl]pyrrolidine Chemical compound C1CCCN1C[C@@H]1CCCN1 YLBWRMSQRFEIEB-VIFPVBQESA-N 0.000 description 2
- XJLYAACHFFNHPV-UHFFFAOYSA-N 2-(3,4-difluoroanilino)-n-[2-methyl-4-(piperazin-1-ylmethyl)phenyl]acetamide;trihydrochloride Chemical compound Cl.Cl.Cl.C=1C=C(NC(=O)CNC=2C=C(F)C(F)=CC=2)C(C)=CC=1CN1CCNCC1 XJLYAACHFFNHPV-UHFFFAOYSA-N 0.000 description 2
- HTMZOECRJRQODE-NRFANRHFSA-N 2-(3,4-difluoroanilino)-n-[2-methyl-5-[[(2s)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]methyl]phenyl]acetamide Chemical compound C([C@@H]1CCCN1CC1=CC=C(C(=C1)NC(=O)CNC=1C=C(F)C(F)=CC=1)C)N1CCCC1 HTMZOECRJRQODE-NRFANRHFSA-N 0.000 description 2
- CWDFHONQSDKIMI-UHFFFAOYSA-N 2-[3,4-difluoro-n-[(2-methylpropan-2-yl)oxycarbonyl]anilino]acetic acid Chemical compound CC(C)(C)OC(=O)N(CC(O)=O)C1=CC=C(F)C(F)=C1 CWDFHONQSDKIMI-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- OEBCLUPLMNBWMR-UHFFFAOYSA-N Cl.Cl.C=1C=C(NC(=O)CNC=2C=C(F)C(F)=CC=2)C(C)=CC=1OC1CCNCC1 Chemical compound Cl.Cl.C=1C=C(NC(=O)CNC=2C=C(F)C(F)=CC=2)C(C)=CC=1OC1CCNCC1 OEBCLUPLMNBWMR-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- CZKMPDNXOGQMFW-UHFFFAOYSA-N chloro(triethyl)germane Chemical compound CC[Ge](Cl)(CC)CC CZKMPDNXOGQMFW-UHFFFAOYSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 229910000365 copper sulfate Inorganic materials 0.000 description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 2
- ZXUQEPZWVQIOJE-UHFFFAOYSA-N methyl 2-chloro-2-oxoacetate Chemical compound COC(=O)C(Cl)=O ZXUQEPZWVQIOJE-UHFFFAOYSA-N 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- ACRBQEDCBONOLX-UHFFFAOYSA-N tert-butyl 4-[(3-amino-4-methylphenyl)methyl]piperazine-1-carboxylate Chemical compound C1=C(N)C(C)=CC=C1CN1CCN(C(=O)OC(C)(C)C)CC1 ACRBQEDCBONOLX-UHFFFAOYSA-N 0.000 description 2
- BBMKAIOZWJLPPF-UHFFFAOYSA-N tert-butyl 4-[(4-methyl-3-nitrophenyl)methyl]piperazine-1-carboxylate Chemical compound C1=C([N+]([O-])=O)C(C)=CC=C1CN1CCN(C(=O)OC(C)(C)C)CC1 BBMKAIOZWJLPPF-UHFFFAOYSA-N 0.000 description 2
- LJKLYFNXUIJTKF-UHFFFAOYSA-N tert-butyl 4-[[3-[[2-[3,4-difluoro-n-[(2-methylpropan-2-yl)oxycarbonyl]anilino]acetyl]amino]-4-methylphenyl]methyl]piperazine-1-carboxylate Chemical compound C1=C(NC(=O)CN(C(=O)OC(C)(C)C)C=2C=C(F)C(F)=CC=2)C(C)=CC=C1CN1CCN(C(=O)OC(C)(C)C)CC1 LJKLYFNXUIJTKF-UHFFFAOYSA-N 0.000 description 2
- MSISANCEQBRCBS-UHFFFAOYSA-N tert-butyl n-(3,4-difluorophenyl)-n-[2-[5-(hydroxymethyl)-2-methylanilino]-2-oxoethyl]carbamate Chemical compound CC1=CC=C(CO)C=C1NC(=O)CN(C(=O)OC(C)(C)C)C1=CC=C(F)C(F)=C1 MSISANCEQBRCBS-UHFFFAOYSA-N 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 2
- 239000003039 volatile agent Substances 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- UVYZMJMDIMWDNJ-UHFFFAOYSA-N (3-amino-2-methylphenyl)methanol Chemical compound CC1=C(N)C=CC=C1CO UVYZMJMDIMWDNJ-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- PKDPUENCROCRCH-UHFFFAOYSA-N 1-piperazin-1-ylethanone Chemical compound CC(=O)N1CCNCC1 PKDPUENCROCRCH-UHFFFAOYSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- CTTUQCIBNSCQRH-UHFFFAOYSA-N 2,3,4-trimethylpentan-3-amine Chemical compound CC(C)C(C)(N)C(C)C CTTUQCIBNSCQRH-UHFFFAOYSA-N 0.000 description 1
- LTSFGZKSGQCZCZ-UHFFFAOYSA-N 2-(3,4-difluoroanilino)-n-(3-hydroxy-2-methylphenyl)acetamide Chemical compound CC1=C(O)C=CC=C1NC(=O)CNC1=CC=C(F)C(F)=C1 LTSFGZKSGQCZCZ-UHFFFAOYSA-N 0.000 description 1
- KZSNCGDIRIZTIH-UHFFFAOYSA-N 2-(3,4-difluoroanilino)-n-[2-methyl-5-(piperazin-1-ylmethyl)phenyl]ethanethioamide Chemical compound C1=C(NC(=S)CNC=2C=C(F)C(F)=CC=2)C(C)=CC=C1CN1CCNCC1 KZSNCGDIRIZTIH-UHFFFAOYSA-N 0.000 description 1
- QLZGREOPQZGKGS-UHFFFAOYSA-N 2-(3,4-difluoroanilino)-n-[3-(hydroxymethyl)-2-methylphenyl]acetamide Chemical compound CC1=C(CO)C=CC=C1NC(=O)CNC1=CC=C(F)C(F)=C1 QLZGREOPQZGKGS-UHFFFAOYSA-N 0.000 description 1
- QMMPZLROQHKLDA-UHFFFAOYSA-N 2-chloro-n-(5-methoxy-2-methylphenyl)acetamide Chemical compound COC1=CC=C(C)C(NC(=O)CCl)=C1 QMMPZLROQHKLDA-UHFFFAOYSA-N 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- AXNUZKSSQHTNPZ-UHFFFAOYSA-N 3,4-difluoroaniline Chemical compound NC1=CC=C(F)C(F)=C1 AXNUZKSSQHTNPZ-UHFFFAOYSA-N 0.000 description 1
- JKRSQNBRNIYETC-UHFFFAOYSA-N 3-(4-methylpiperazin-1-yl)propan-1-ol Chemical compound CN1CCN(CCCO)CC1 JKRSQNBRNIYETC-UHFFFAOYSA-N 0.000 description 1
- RGQUXGFSHXDXIE-UHFFFAOYSA-N 3-[[tert-butyl(dimethyl)silyl]oxymethyl]-2-methylaniline Chemical compound CC1=C(N)C=CC=C1CO[Si](C)(C)C(C)(C)C RGQUXGFSHXDXIE-UHFFFAOYSA-N 0.000 description 1
- XXHAQKRFEWUTOU-UHFFFAOYSA-N 3-[tert-butyl(dimethyl)silyl]oxy-2-methylaniline Chemical compound CC1=C(N)C=CC=C1O[Si](C)(C)C(C)(C)C XXHAQKRFEWUTOU-UHFFFAOYSA-N 0.000 description 1
- BYHMLZGICSEKIY-UHFFFAOYSA-N 3-amino-2-methylbenzoic acid Chemical compound CC1=C(N)C=CC=C1C(O)=O BYHMLZGICSEKIY-UHFFFAOYSA-N 0.000 description 1
- FLROJJGKUKLCAE-UHFFFAOYSA-N 3-amino-2-methylphenol Chemical compound CC1=C(N)C=CC=C1O FLROJJGKUKLCAE-UHFFFAOYSA-N 0.000 description 1
- YSEMCVGMNUUNRK-UHFFFAOYSA-N 3-chloro-4-fluoroaniline Chemical compound NC1=CC=C(F)C(Cl)=C1 YSEMCVGMNUUNRK-UHFFFAOYSA-N 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- ONCSETSNSQARED-UHFFFAOYSA-N 4-(4-amino-3-methylphenyl)piperazine-1-carboxylic acid Chemical compound C1=C(N)C(C)=CC(N2CCN(CC2)C(O)=O)=C1 ONCSETSNSQARED-UHFFFAOYSA-N 0.000 description 1
- DLTKEOYTIZIUKD-UHFFFAOYSA-N 4-(chloromethyl)-1-methyl-2-nitrobenzene Chemical compound CC1=CC=C(CCl)C=C1[N+]([O-])=O DLTKEOYTIZIUKD-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- JHFOWEGCZWLHNW-UHFFFAOYSA-N 4-fluoro-2-methyl-1-nitrobenzene Chemical compound CC1=CC(F)=CC=C1[N+]([O-])=O JHFOWEGCZWLHNW-UHFFFAOYSA-N 0.000 description 1
- RPJXLEZOFUNGNZ-UHFFFAOYSA-N 5-methoxy-2-methylaniline Chemical compound COC1=CC=C(C)C(N)=C1 RPJXLEZOFUNGNZ-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- IMVKMGAFUYLXEC-UHFFFAOYSA-N C(C)(C)(C)[SiH2]OC(C=1C(=C(C=CC=1)NC(CCl)=O)C)(C)C Chemical compound C(C)(C)(C)[SiH2]OC(C=1C(=C(C=CC=1)NC(CCl)=O)C)(C)C IMVKMGAFUYLXEC-UHFFFAOYSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 101100293260 Homo sapiens NAA15 gene Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 108010092694 L-Selectin Proteins 0.000 description 1
- 102000016551 L-selectin Human genes 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- 102100026781 N-alpha-acetyltransferase 15, NatA auxiliary subunit Human genes 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 102100037602 P2X purinoceptor 7 Human genes 0.000 description 1
- 101710189965 P2X purinoceptor 7 Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- AHPKEZZXQIYJFB-UHFFFAOYSA-H [F-].[F-].[F-].[F-].[F-].[F-].Br[P+](N1CCCC1)(N1CCCC1)N1CCCC1.Br[P+](N1CCCC1)(N1CCCC1)N1CCCC1.Br[P+](N1CCCC1)(N1CCCC1)N1CCCC1.Br[P+](N1CCCC1)(N1CCCC1)N1CCCC1.Br[P+](N1CCCC1)(N1CCCC1)N1CCCC1.Br[P+](N1CCCC1)(N1CCCC1)N1CCCC1 Chemical compound [F-].[F-].[F-].[F-].[F-].[F-].Br[P+](N1CCCC1)(N1CCCC1)N1CCCC1.Br[P+](N1CCCC1)(N1CCCC1)N1CCCC1.Br[P+](N1CCCC1)(N1CCCC1)N1CCCC1.Br[P+](N1CCCC1)(N1CCCC1)N1CCCC1.Br[P+](N1CCCC1)(N1CCCC1)N1CCCC1.Br[P+](N1CCCC1)(N1CCCC1)N1CCCC1 AHPKEZZXQIYJFB-UHFFFAOYSA-H 0.000 description 1
- OQMHGSBAUHIRJR-UHFFFAOYSA-M [I-].[K+].C(C)(C)(C)OC(=O)N1CCN(CC1)C1=CC(=C(C=C1)Cl)NC(CNC1=CC(=C(C=C1)F)F)=O Chemical compound [I-].[K+].C(C)(C)(C)OC(=O)N1CCN(CC1)C1=CC(=C(C=C1)Cl)NC(CNC1=CC(=C(C=C1)F)F)=O OQMHGSBAUHIRJR-UHFFFAOYSA-M 0.000 description 1
- 150000003869 acetamides Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000036428 airway hyperreactivity Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- ROCRREBHOVWFAD-UHFFFAOYSA-N bromo carbonochloridate Chemical compound ClC(=O)OBr ROCRREBHOVWFAD-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- KOPOQZFJUQMUML-UHFFFAOYSA-N chlorosilane Chemical compound Cl[SiH3] KOPOQZFJUQMUML-UHFFFAOYSA-N 0.000 description 1
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 238000006193 diazotization reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 1
- AMGWDYLEMSMUIO-UHFFFAOYSA-N ethyl 5-bromo-2-chlorobenzoate Chemical compound CCOC(=O)C1=CC(Br)=CC=C1Cl AMGWDYLEMSMUIO-UHFFFAOYSA-N 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- CVVIJWRCGSYCMB-UHFFFAOYSA-N hydron;piperazine;dichloride Chemical compound Cl.Cl.C1CNCCN1 CVVIJWRCGSYCMB-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229940031993 lithium benzoate Drugs 0.000 description 1
- IIEJLLOYMIUQEV-UHFFFAOYSA-M lithium;2-chloro-5-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]benzoate Chemical compound [Li+].C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=C(Cl)C(C([O-])=O)=C1 IIEJLLOYMIUQEV-UHFFFAOYSA-M 0.000 description 1
- LDJNSLOKTFFLSL-UHFFFAOYSA-M lithium;benzoate Chemical compound [Li+].[O-]C(=O)C1=CC=CC=C1 LDJNSLOKTFFLSL-UHFFFAOYSA-M 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 210000003584 mesangial cell Anatomy 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- FTHZVHUTKASCAM-UHFFFAOYSA-N methyl 3-[(2-chloroacetyl)amino]-2-methylbenzoate Chemical compound COC(=O)C1=CC=CC(NC(=O)CCl)=C1C FTHZVHUTKASCAM-UHFFFAOYSA-N 0.000 description 1
- IGLDDPHSKGICIH-UHFFFAOYSA-N methyl 3-[[2-(3,4-difluoroanilino)acetyl]amino]-2-methylbenzoate Chemical compound COC(=O)C1=CC=CC(NC(=O)CNC=2C=C(F)C(F)=CC=2)=C1C IGLDDPHSKGICIH-UHFFFAOYSA-N 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 1
- CQKMOGNTMDERNX-UHFFFAOYSA-N n-[3-[tert-butyl(dimethyl)silyl]oxy-2-methylphenyl]-2-(3,4-difluoroanilino)acetamide Chemical compound C1=CC=C(O[Si](C)(C)C(C)(C)C)C(C)=C1NC(=O)CNC1=CC=C(F)C(F)=C1 CQKMOGNTMDERNX-UHFFFAOYSA-N 0.000 description 1
- BGMLNDWDUVXCGU-UHFFFAOYSA-N n-[3-[tert-butyl(dimethyl)silyl]oxy-2-methylphenyl]-2-chloroacetamide Chemical compound CC1=C(NC(=O)CCl)C=CC=C1O[Si](C)(C)C(C)(C)C BGMLNDWDUVXCGU-UHFFFAOYSA-N 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 210000003681 parotid gland Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000004634 pharmacological analysis method Methods 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- UOUFRTFWWBCVPV-UHFFFAOYSA-N tert-butyl 4-(2,4-dioxo-1H-thieno[3,2-d]pyrimidin-3-yl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CC1)n1c(=O)[nH]c2ccsc2c1=O UOUFRTFWWBCVPV-UHFFFAOYSA-N 0.000 description 1
- STULOYQZKIGXJD-UHFFFAOYSA-N tert-butyl 4-(3-amino-4-chlorophenyl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=C(Cl)C(N)=C1 STULOYQZKIGXJD-UHFFFAOYSA-N 0.000 description 1
- DJXLXFWWETVERO-UHFFFAOYSA-N tert-butyl 4-(3-methyl-4-nitrophenyl)piperazine-1-carboxylate Chemical compound C1=C([N+]([O-])=O)C(C)=CC(N2CCN(CC2)C(=O)OC(C)(C)C)=C1 DJXLXFWWETVERO-UHFFFAOYSA-N 0.000 description 1
- VNSADFANVQEHLX-UHFFFAOYSA-N tert-butyl 4-[4-chloro-3-[(2-chloroacetyl)amino]phenyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=C(Cl)C(NC(=O)CCl)=C1 VNSADFANVQEHLX-UHFFFAOYSA-N 0.000 description 1
- LHRAKTKVOGSTOX-UHFFFAOYSA-N tert-butyl 4-[4-chloro-3-[[2-(3,4-difluoroanilino)acetyl]amino]phenyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=C(Cl)C(NC(=O)CNC=2C=C(F)C(F)=CC=2)=C1 LHRAKTKVOGSTOX-UHFFFAOYSA-N 0.000 description 1
- QUCKXVJHHKXWKP-UHFFFAOYSA-N tert-butyl 4-[[3-[[2-[3,4-difluoro-n-[(2-methylpropan-2-yl)oxycarbonyl]anilino]ethanethioyl]amino]-4-methylphenyl]methyl]piperazine-1-carboxylate Chemical compound C1=C(NC(=S)CN(C(=O)OC(C)(C)C)C=2C=C(F)C(F)=CC=2)C(C)=CC=C1CN1CCN(C(=O)OC(C)(C)C)CC1 QUCKXVJHHKXWKP-UHFFFAOYSA-N 0.000 description 1
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- BBWOUFKXQSRMCV-UHFFFAOYSA-N tert-butyl n-(3,4-difluorophenyl)-n-[2-(4-hydroxy-2-methylanilino)-2-oxoethyl]carbamate Chemical compound CC1=CC(O)=CC=C1NC(=O)CN(C(=O)OC(C)(C)C)C1=CC=C(F)C(F)=C1 BBWOUFKXQSRMCV-UHFFFAOYSA-N 0.000 description 1
- GPDNFOVPIXJFKQ-UHFFFAOYSA-N tert-butyl n-[1-(3-amino-4-methylphenyl)pyrrolidin-3-yl]carbamate Chemical compound C1=C(N)C(C)=CC=C1N1CC(NC(=O)OC(C)(C)C)CC1 GPDNFOVPIXJFKQ-UHFFFAOYSA-N 0.000 description 1
- UVBRUZYDIQHLTQ-UHFFFAOYSA-N tert-butyl n-[1-(3-methyl-4-nitrophenyl)pyrrolidin-3-yl]carbamate Chemical compound C1=C([N+]([O-])=O)C(C)=CC(N2CC(CC2)NC(=O)OC(C)(C)C)=C1 UVBRUZYDIQHLTQ-UHFFFAOYSA-N 0.000 description 1
- RQCNHUCCQJMSRG-UHFFFAOYSA-N tert-butyl piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1 RQCNHUCCQJMSRG-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9901875A SE9901875D0 (sv) | 1999-05-25 | 1999-05-25 | Novel compounds |
| SE9901875-6 | 1999-05-25 | ||
| PCT/GB2000/001943 WO2000071529A1 (en) | 1999-05-25 | 2000-05-22 | Substituted phenyl compounds with immunosuppressing activity and pharmaceutical compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003500399A true JP2003500399A (ja) | 2003-01-07 |
| JP2003500399A5 JP2003500399A5 (enExample) | 2007-06-28 |
Family
ID=20415710
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000619786A Pending JP2003500399A (ja) | 1999-05-25 | 2000-05-22 | 免疫抑制活性を有する置換フェニル化合物および医薬組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6555541B1 (enExample) |
| EP (1) | EP1185522A1 (enExample) |
| JP (1) | JP2003500399A (enExample) |
| KR (1) | KR20020012583A (enExample) |
| CN (1) | CN1351598A (enExample) |
| AU (1) | AU778305B2 (enExample) |
| BR (1) | BR0010716A (enExample) |
| CA (1) | CA2372580A1 (enExample) |
| IL (2) | IL146187A0 (enExample) |
| MX (1) | MXPA01011957A (enExample) |
| NO (1) | NO322166B1 (enExample) |
| NZ (1) | NZ515282A (enExample) |
| SE (1) | SE9901875D0 (enExample) |
| WO (1) | WO2000071529A1 (enExample) |
| ZA (1) | ZA200109091B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005107804A1 (ja) * | 2004-05-06 | 2005-11-17 | Ono Pharmaceutical Co., Ltd. | 呼吸器疾患治療剤 |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9902270D0 (sv) | 1999-06-16 | 1999-06-16 | Astra Ab | Pharmaceutically active compounds |
| SE9904505D0 (sv) | 1999-12-09 | 1999-12-09 | Astra Pharma Prod | Novel compounds |
| TWI258462B (en) | 1999-12-17 | 2006-07-21 | Astrazeneca Ab | Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same |
| SE9904738D0 (sv) * | 1999-12-22 | 1999-12-22 | Astra Pharma Prod | Novel compounds |
| SE9904765D0 (sv) | 1999-12-23 | 1999-12-23 | Astra Ab | Pharmaceutically-useful compounds |
| US6808924B1 (en) | 2000-07-11 | 2004-10-26 | Claudia Lanari | Mouse mammary tumor lines expressing estrogen and progesterone receptors |
| WO2003042190A1 (en) | 2001-11-12 | 2003-05-22 | Pfizer Products Inc. | N-alkyl-adamantyl derivatives as p2x7-receptor antagonists |
| PA8557501A1 (es) | 2001-11-12 | 2003-06-30 | Pfizer Prod Inc | Benzamida, heteroarilamida y amidas inversas |
| CA2509700A1 (en) * | 2002-12-20 | 2004-07-08 | Sasol Technology (Pty) Limited | Tandem tetramerisation-polymerisation of olefins |
| US7071223B1 (en) | 2002-12-31 | 2006-07-04 | Pfizer, Inc. | Benzamide inhibitors of the P2X7 receptor |
| PA8591801A1 (es) | 2002-12-31 | 2004-07-26 | Pfizer Prod Inc | Inhibidores benzamidicos del receptor p2x7. |
| AR042941A1 (es) * | 2003-01-27 | 2005-07-06 | Fujisawa Pharmaceutical Co | Derivados de tiazol, su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos inhibidores de la proteina-1 de adhesion vascular (vap-1) |
| DE10306250A1 (de) * | 2003-02-14 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US7223788B2 (en) | 2003-02-14 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments |
| EP1763353A1 (en) * | 2004-06-29 | 2007-03-21 | Warner-Lambert Company LLC | COMBINATION THERAPIES UTILIZING BENZAMIDE INHIBITORS OF THE P2X<sb>7</sb> RECEPTOR |
| WO2006003500A1 (en) * | 2004-06-29 | 2006-01-12 | Pfizer Products Inc. | Method for preparing 5-`4-(2-hydroxy-propyl)-3,5-dioxo-4,5-dihydro-3h`1,2,4!triazin-2-yl!-benzamide derivatives by deprotecting the hydroxyl-protected precursers |
| MXPA06015273A (es) * | 2004-06-29 | 2007-03-15 | Pfizer Prod Inc | Procedimiento para preparar derivados de 5-[4-(2-hidroxi -etil)-3, 5-dioxo-4, 5-dihidro-3h-[1, 2, 4]-triazin -2-il]-benzamida con actividad inhibidora de p2x7 mediante reaccion del derivado no sustituido en posicion 4 de la triazina con un oxirano en |
| CA2645551C (en) | 2006-03-16 | 2016-06-28 | Renovis, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
| TWI464148B (zh) | 2006-03-16 | 2014-12-11 | Evotec Us Inc | 作為p2x7調節劑之雙環雜芳基化合物與其用途 |
| DK2001474T3 (en) | 2006-03-16 | 2016-05-09 | Second Genome Inc | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND APPLICATIONS THEREOF |
| JP2010520875A (ja) | 2007-03-09 | 2010-06-17 | レノビス, インコーポレイテッド | P2x7調節因子としてのビシクロヘテロアリール化合物およびその使用 |
| BRPI0910034B1 (pt) | 2008-03-25 | 2022-02-08 | Affectis Pharmaceuticals Ag | Antagonistas do p2x7r e composições farmacêuticas que os compreendem |
| AU2010237302A1 (en) | 2009-04-14 | 2011-12-01 | Affectis Pharmaceuticals Ag | Novel P2X7R antagonists and their use |
| EP2322149A1 (en) | 2009-11-03 | 2011-05-18 | Universidad del Pais Vasco | Methods and compositions for the treatment of ischemia |
| SG185400A1 (en) | 2010-05-14 | 2012-12-28 | Affectis Pharmaceuticals Ag | Novel methods for the preparation of p2x7r antagonists |
| US8609672B2 (en) | 2010-08-27 | 2013-12-17 | University Of The Pacific | Piperazinylpyrimidine analogues as protein kinase inhibitors |
| WO2012110190A1 (en) | 2011-02-17 | 2012-08-23 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| WO2012163792A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| WO2012163456A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| GB2508652A (en) * | 2012-12-07 | 2014-06-11 | Agency Science Tech & Res | Heterocyclic piperazine derivatives |
| CN105712923A (zh) * | 2014-12-03 | 2016-06-29 | 江苏先声药业有限公司 | 一种尼达尼布杂质及其制备方法与应用 |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2623228A1 (de) * | 1976-05-24 | 1977-12-01 | Merckle Kg Chem Pharm L | N-acyl substituierte benzamide, verfahren zu ihrer herstellung und arzneimittel enthaltend solche benzamide |
| US4294851A (en) * | 1977-07-04 | 1981-10-13 | Gunter Metz | Aminobenzoic acid derivatives |
| JPS57171904A (en) * | 1981-04-15 | 1982-10-22 | Mitsubishi Petrochem Co Ltd | Tri- or tetra-substituted phenoxycarboxylic acid anilide type herbicide |
| JPS5824137A (ja) * | 1981-07-06 | 1983-02-14 | イ−ストマン・コダツク・カンパニ− | 発色性色素プレカーサ化合物 |
| JPS62253168A (ja) * | 1986-04-25 | 1987-11-04 | Konika Corp | 色素画像の安定性を改良したハロゲン化銀写真感光材料 |
| JPS62291653A (ja) * | 1986-06-11 | 1987-12-18 | Konica Corp | ハロゲン化銀写真感光材料 |
| JPH02209856A (ja) * | 1989-02-09 | 1990-08-21 | Toyobo Co Ltd | 新規置換アセトアミド化合物 |
| WO1998035944A1 (en) * | 1997-02-14 | 1998-08-20 | Bayer Corporation | Amides as npy5 receptor antagonists |
| JPH1171336A (ja) * | 1997-06-25 | 1999-03-16 | Mitsubishi Chem Corp | アミド誘導体 |
| WO1999029686A1 (en) * | 1997-12-05 | 1999-06-17 | Astrazeneca Uk Limited | Novel compounds |
| JP2000053570A (ja) * | 1998-08-05 | 2000-02-22 | Nippon Soda Co Ltd | フェニルイミダゾール系抗高脂血症薬 |
-
1999
- 1999-05-25 SE SE9901875A patent/SE9901875D0/xx unknown
-
2000
- 2000-05-22 AU AU49362/00A patent/AU778305B2/en not_active Ceased
- 2000-05-22 NZ NZ515282A patent/NZ515282A/xx unknown
- 2000-05-22 US US09/583,000 patent/US6555541B1/en not_active Expired - Fee Related
- 2000-05-22 JP JP2000619786A patent/JP2003500399A/ja active Pending
- 2000-05-22 IL IL14618700A patent/IL146187A0/xx active IP Right Grant
- 2000-05-22 CA CA002372580A patent/CA2372580A1/en not_active Abandoned
- 2000-05-22 WO PCT/GB2000/001943 patent/WO2000071529A1/en not_active Ceased
- 2000-05-22 KR KR1020017015027A patent/KR20020012583A/ko not_active Ceased
- 2000-05-22 CN CN00808036A patent/CN1351598A/zh active Pending
- 2000-05-22 BR BR0010716-6A patent/BR0010716A/pt not_active Application Discontinuation
- 2000-05-22 MX MXPA01011957A patent/MXPA01011957A/es active IP Right Grant
- 2000-05-22 EP EP00931406A patent/EP1185522A1/en not_active Withdrawn
-
2001
- 2001-10-25 IL IL146187A patent/IL146187A/en not_active IP Right Cessation
- 2001-11-02 ZA ZA200109091A patent/ZA200109091B/xx unknown
- 2001-11-20 NO NO20015665A patent/NO322166B1/no unknown
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2623228A1 (de) * | 1976-05-24 | 1977-12-01 | Merckle Kg Chem Pharm L | N-acyl substituierte benzamide, verfahren zu ihrer herstellung und arzneimittel enthaltend solche benzamide |
| US4294851A (en) * | 1977-07-04 | 1981-10-13 | Gunter Metz | Aminobenzoic acid derivatives |
| JPS57171904A (en) * | 1981-04-15 | 1982-10-22 | Mitsubishi Petrochem Co Ltd | Tri- or tetra-substituted phenoxycarboxylic acid anilide type herbicide |
| JPS5824137A (ja) * | 1981-07-06 | 1983-02-14 | イ−ストマン・コダツク・カンパニ− | 発色性色素プレカーサ化合物 |
| JPS62253168A (ja) * | 1986-04-25 | 1987-11-04 | Konika Corp | 色素画像の安定性を改良したハロゲン化銀写真感光材料 |
| JPS62291653A (ja) * | 1986-06-11 | 1987-12-18 | Konica Corp | ハロゲン化銀写真感光材料 |
| JPH02209856A (ja) * | 1989-02-09 | 1990-08-21 | Toyobo Co Ltd | 新規置換アセトアミド化合物 |
| WO1998035944A1 (en) * | 1997-02-14 | 1998-08-20 | Bayer Corporation | Amides as npy5 receptor antagonists |
| JPH1171336A (ja) * | 1997-06-25 | 1999-03-16 | Mitsubishi Chem Corp | アミド誘導体 |
| WO1999029686A1 (en) * | 1997-12-05 | 1999-06-17 | Astrazeneca Uk Limited | Novel compounds |
| JP2000053570A (ja) * | 1998-08-05 | 2000-02-22 | Nippon Soda Co Ltd | フェニルイミダゾール系抗高脂血症薬 |
Non-Patent Citations (1)
| Title |
|---|
| JOURNAL OF MEDICINAL CHEMISTRY, vol. 26(7), JPN6010023837, 1983, pages 1065 - 1070, ISSN: 0001605965 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005107804A1 (ja) * | 2004-05-06 | 2005-11-17 | Ono Pharmaceutical Co., Ltd. | 呼吸器疾患治療剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000071529A1 (en) | 2000-11-30 |
| BR0010716A (pt) | 2002-02-13 |
| KR20020012583A (ko) | 2002-02-16 |
| EP1185522A1 (en) | 2002-03-13 |
| NZ515282A (en) | 2004-01-30 |
| NO20015665D0 (no) | 2001-11-20 |
| CA2372580A1 (en) | 2000-11-30 |
| MXPA01011957A (es) | 2002-05-06 |
| US6555541B1 (en) | 2003-04-29 |
| AU4936200A (en) | 2000-12-12 |
| CN1351598A (zh) | 2002-05-29 |
| IL146187A (en) | 2007-06-17 |
| AU778305B2 (en) | 2004-11-25 |
| NO322166B1 (no) | 2006-08-21 |
| ZA200109091B (en) | 2003-04-30 |
| IL146187A0 (en) | 2002-07-25 |
| NO20015665L (no) | 2002-01-24 |
| SE9901875D0 (sv) | 1999-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003500399A (ja) | 免疫抑制活性を有する置換フェニル化合物および医薬組成物 | |
| JP2003500399A5 (enExample) | ||
| JP3210771B2 (ja) | アリールアセタマイド | |
| KR100752033B1 (ko) | 신규 화합물 | |
| JP2810236B2 (ja) | ナフタレン誘導体 | |
| ES2289691T3 (es) | Derivados de sulfonamida para el tratamiento de enfermedades. | |
| AU2005225632A1 (en) | Formamide derivatives useful as adrenoceptor | |
| JP2000504677A (ja) | 5ht7レセプター・アンタゴニスト用のスルホンアミド誘導体 | |
| WO2005092861A1 (en) | Quinolinone derivatives pharmaceutical compositions containing them and their use | |
| RS50561B (sr) | Derivati sulfonamida za lečenje bolesti | |
| KR20140097127A (ko) | 아닐린 유도체, 그의 제조법 및 그의 치료 용도 | |
| SK132498A3 (en) | Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase | |
| JP6498672B2 (ja) | 疼痛に対して多重モードの活性を有するピペリジン化合物 | |
| JP4221447B1 (ja) | ムスカリン様受容体アンタゴニストとしてのカルボキサミド誘導体 | |
| DE60316683T2 (de) | Phenylcyclohexylpropanolaminderivate, deren herstellung und therapeutsche anwendung | |
| JPH021439A (ja) | ジアミン化合物、その製法及び該化合物を含有する高血圧症及び炎症を治療するための医薬 | |
| US5498628A (en) | Naphthamide derivatives | |
| JP4054366B2 (ja) | 疾患の治療のために有用な化合物 | |
| US4971990A (en) | Phenoxyethylamine derivatives, for preparing the same and composition for exhibiting excellent α1 -blocking activity containing the same | |
| CA1094070A (en) | 1-phenyl-piperazine derivatives | |
| CA2603030C (en) | Benzyloxypropylamine derivative | |
| JP3190588B2 (ja) | ヒドロキサム酸化合物 | |
| JPH0143746B2 (enExample) | ||
| JPS58159469A (ja) | 新規な1,3位ジ置換3−アミノインダゾ−ル誘導体およびその製造法 | |
| NZ549839A (en) | Formamide derivatives useful as adrenoceptor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20070511 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070511 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100427 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20100428 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20101005 |